Biogen's Diranersen Shows Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease
At two years, diranersen 60 mg administered twice yearly slowed clinical decline by 38% on the CDR-SB scale, equivalent to a 1.09-point treatment difference Compared with 18 months,…
At two years, diranersen 60 mg administered twice yearly slowed clinical decline by 38% on the CDR-SB scale, equivalent to a 1.09-point treatment difference
Compared with 18 months, the 60 mg dose group showed greater slowing of clinical decline on 5 of 6 measures at two years
Clinical benefit was observed across all studied doses, with the 60 mg dose group demonstrating compelling efficacy and a favorable benefit-risk profile
Data presented at the Clinical Trials on Alzheimer's Disease conference
CAMBRIDGE, Mass., November 17, 2026 -- Biogen Inc. today announced new data from the Phase 2 CELIA study showing that diranersen demonstrated increasing clinical benefit at two years in patients with early Alzheimer's disease. Results presented at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference showed slowed clinical decline across multiple measures of cognition, function, and disease progression, with the 60 mg twice-yearly dosing regimen showing the greatest treatment effect at two years.
"These two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit but also an increase in the magnitude of effect at two years," said Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen. "These findings strengthen the growing body of evidence supporting tau as a therapeutic target and highlight the potential of diranersen to meaningfully impact disease progression in people with early Alzheimer's disease."
"These are very encouraging results, particularly given the progressive nature of Alzheimer's disease," said Lawren VandeVrede, M.D., Ph.D., principal investigator of the Phase 2 CELIA study at the University of California, San Francisco. "The widening difference observed between 18 months and two years is notable and clinically meaningful. For patients and families, slowing clinical decline means more time in the early stages, maintaining independence, and staying connected to the people and experiences that matter most."
At two years, the analysis showed that diranersen continued to slow clinical decline across measures of cognition, function, and disease progression. Clinical benefit was observed across all studied doses, with the 60 mg twice-yearly dosing regimen showing the greatest treatment effect at two years. Diranersen was generally well tolerated over two years, with no new safety signals observed.
Clinical outcomes for the 60 mg twice-yearly dosing regimen versus participants originally randomized to placebo
Week 76 Week 96
CDR-SB 26% 38%*
ADAS-Cog13 42% 54%
MMSE 50% 38%
ADCS-ADL-MCI 0% 30%
ADCOMS 23% 38%
Modified iADRS 30% 46%
* Equivalent to a 1.09-point treatment difference on the CDR-SB scale at Week 96
The two-year analysis derives from the ongoing open-label extension phase of CELIA. Treatment effects were calculated by comparing participants who received diranersen during the placebo-controlled phase of the study and remained on the same dose through two years, with participants originally assigned to placebo who transitioned to the extension phase. At Week 96, participants in the placebo group had either not received diranersen or received only a single dose after transitioning to the extension phase, providing an equivalent placebo control group. As the study progresses, all participants in the extension phase are expected to receive diranersen.
In addition to the two-year results, Biogen also presented new 18-month placebo-controlled clinical and biomarker findings from CELIA that further support the effect of diranersen. At 18 months, a subgroup analysis of diranersen 60 mg twice yearly showed preferential efficacy on memory, orientation, and executive function. Diranersen also significantly reduced tau PET signal across broad brain regions, CSF p-tau181, and plasma p-tau217. These data build on previously reported results from the Phase 2 CELIA study and further support the continued development of diranersen in people with early Alzheimer's disease.
Frequently Asked Questions
1. What do the two-year data show?
At two years, CELIA showed slowed clinical decline across multiple measures of cognition, function, and disease progression. With the 60 mg twice-yearly dosing regimen, clinical benefit increased over time and was greatest at two years. The treatment effect on CDR-SB increased from 26% to 38%, ADAS-Cog13 from 42% to 54%, ADCS-ADL-MCI from 0% to 30%, ADCOMS from 23% to 38%, and modified iADRS from 30% to 46%. Together, these findings indicate a greater magnitude of clinical benefit at two years compared with 18 months.
2. How should we interpret the clinical benefit observed at two years?
With the 60 mg twice-yearly dosing regimen, participants showed a 1.09-point treatment difference on the Clinical Dementia Rating Scale Sum of Boxes. Clinicians generally consider a 1-point difference on the CDR-SB scale to be highly meaningful, and the clinical benefit of diranersen observed in CELIA exceeded this threshold at two years.
3. What do these findings mean for people with early Alzheimer's disease and their families?
The two-year results from CELIA provide encouraging evidence that diranersen has the potential to slow clinical decline in people with early Alzheimer's disease. These Phase 2 findings support the continued development of diranersen and further evaluation in Phase 3 trials designed to confirm its efficacy and safety. However, diranersen remains an investigational therapy and has not been approved by any regulatory authority.
4. Why is the 60 mg twice-yearly dosing regimen important?
Clinical benefit was observed across all doses in the CELIA study, with the 60 mg twice-yearly dosing regimen demonstrating compelling efficacy and a favorable benefit-risk profile, supporting its continued development.
5. Why is tau an important target in Alzheimer's disease, and how does diranersen work?
Tau protein is a core pathology of Alzheimer's disease and is closely associated with disease progression and cognitive decline. Diranersen is an investigational antisense oligonucleotide designed to target MAPT mRNA and reduce production of all tau protein isoforms, thereby lowering both intracellular and extracellular tau. Results from CELIA add to the growing body of evidence supporting tau as an important therapeutic target and provide further evidence that this novel mechanism may translate into meaningful clinical benefit.
Biogen Safe Harbor Statement
This news release contains forward-looking statements, including statements relating to: the potential benefits, efficacy, and safety of diranersen; the potential clinical effects of diranersen; the clinical development program, clinical trials, data readouts, and presentations relating to diranersen; the treatment of Alzheimer's disease and the relationship between tau and Alzheimer's disease; the potential for diranersen, if confirmed in Phase 3 trials, to represent a new approach to treating one of the core pathologies of Alzheimer's disease; potential regulatory discussions, submissions, decisions, and approvals and their timing; the expected benefits, risks, and potential of our collaboration arrangements; the potential of our commercial business and pipeline programs; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as "aim," "anticipate," "assume," "believe," "consider," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "might," "objective," "outlook," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs ultimately result in commercialization of a product. Results from early clinical trials may not be representative of full results or results from later or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. These statements involve significant risks and uncertainties, may be based on inaccurate assumptions, and could cause actual results to differ materially from those reflected in such statements, given their forward-looking nature. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. By their nature, we cannot guarantee that any of the outcomes expressed in these forward-looking statements will be realized, in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are beyond our control, and could cause future events or results to differ materially from those stated or implied in this document, including but not limited to: uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects, and timing with respect to product approvals, approvals of additional indications for existing products, sales, pricing, growth, reimbursement, and launches of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industries and any other markets in which we compete, including increased competition from new originator products, generics of existing products, prodrugs, and biosimilars, as well as products approved under abbreviated regulatory pathways; our ability to effectively execute our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers of growth in our business, including our reliance on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business that are outside our full control; risks associated with biosimilar commercialization, a business that is subject to risks related to our reliance on third parties, intellectual property, competition, and market challenges, and regulatory compliance; the risk that positive results from clinical trials may not be reproduced in subsequent or confirmatory trials, or that success in early clinical trials may not be predictive of results in later or large-scale trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, the possibility that additional data or analyses obtained during clinical trials may raise unexpected concerns, the possibility that regulators may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use of our products, or product liability claims; and any other risks and uncertainties described in our reports filed with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. These statements speak only as of the date of this news release and are based on information and estimates available to us at that time. If known or unknown risks or uncertainties materialize, or if underlying assumptions prove inaccurate, actual results could differ materially from past results and from anticipated, estimated, or projected results. Investors are cautioned not to place undue reliance on forward-looking statements. A further list and description of risks, uncertainties, and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent Quarterly Reports on Form 10-Q. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, changes in circumstances, or otherwise, except as required by law.
Digital Media Disclosure
We use and expect to continue to use our Investor Relations website, Biogen LinkedIn account, and Biogen X account as a means of disclosing material non-public information to the public in a broad, non-exclusionary manner, including for the purpose of complying with our disclosure obligations under the SEC's Regulation Fair Disclosure. Accordingly, investors should monitor our Investor Relations website and this social media channel, in addition to following our press releases, SEC filings, public conference calls, and webcasts, as information posted on these platforms may be material to investors.
insigtX content is informational and educational, not investment advice.